XML 58 R46.htm IDEA: XBRL DOCUMENT
v3.23.1

Investments - Schedule of Fair Value Portfolio By Industry Sector (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2023 | Dec. 31, 2022
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | $ 3,130,178 | $ 2,963,955
Drug Discovery & Development |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 1,220,057 | 1,150,707
Consumer & Business Products |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 2,593 | 2,821
Software |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 828,712 | 798,264
Consumer & Business Services |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 474,883 | 439,384
Communications & Networking |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 107,201 | 101,833
Healthcare Services Other |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 214,199 | 198,763
Information Services |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 62,039 | 60,759
Diversified Financial Services |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 87,805 | 68,569
Manufacturing Technology |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 48,993 | 46,109
Biotechnology Tools [Member] |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 33,032 | 32,825
Media Content Info [Member] |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 9,956 | 35
Drug Delivery |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 23 | 90
Medical Devices & Equipment |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 1,155 | 1,834
Surgical Devices |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 4,189 | 3,038
Electronics & Computer Hardware |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 21,476 | 21,517
Semiconductors |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | 966 | 21,921
Sustainable And Renewable Technology |  |
Schedule Of Investments [Line Items] |  |
Investments at Fair Value | $ 12,899 | $ 15,486
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 100.00% | 100.00%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Discovery & Development |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 39.00% | 38.80%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Consumer & Business Products |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.10% | 0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Software |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 26.50% | 26.90%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Consumer & Business Services |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 15.20% | 14.80%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Communications & Networking |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 3.40% | 3.50%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Healthcare Services Other |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 6.80% | 6.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Information Services |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 2.00% | 2.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Diversified Financial Services |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 2.80% | 2.30%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Manufacturing Technology |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 1.60% | 1.60%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Biotechnology Tools [Member] |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 1.10% | 1.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Media Content Info [Member] |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.30% | 0.00%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Delivery |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.00% | 0.00%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Medical Devices & Equipment |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.00% | 0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Surgical Devices |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.10% | 0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Electronics & Computer Hardware |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.70% | 0.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Semiconductors |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.00% | 0.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Sustainable And Renewable Technology |  |
Schedule Of Investments [Line Items] |  |
Concentration Risk, Percentage | 0.40% | 0.50%

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 5D -Subparagraph (SX 210.12-13D(Column C)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ScheduleOfInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_DrugDiscoveryAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_ConsumerAndBusinessProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_ConsumerAndBusinessServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_CommunicationsAndNetworkingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_HealthcareServicesOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_InformationServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_DiversifiedFinancialServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_ManufacturingTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_BiotechnologyToolsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_MediaContentInfoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_DrugDeliveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_MedicalDevicesAndEquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SurgicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_ElectronicsComputerHardwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SemiconductorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquitySecuritiesByIndustryAxis=htgc_SustainableAndRenewableTechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=htgc_IndustrySubSectorConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |